CONCORD DRUGS
Concord Drugs Share Price
Concord Drugs Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Concord Drugs Investment Rating
-
Master Rating:
-
Concord Drugs has an operating revenue of Rs. 51.30 Cr. on a trailing 12-month basis. An annual revenue growth of 15% is outstanding, Pre-tax margin of 4% needs improvement, ROE of 5% is fair but needs improvement. The company has a reasonable debt to equity of 9%, which signals a healthy balance sheet. From an O'Neil Methodology perspective, the stock has an EPS Rank of 43 which is a POOR score indicating inconsistency in earnings, a RS Rating of 29 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C- which is evident from recent supply seen, Group Rank of 111 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of E is the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.
EPS Strength
Price Strength
Buyer Demand
Group Rank
- Indicator
- Jun 2022
- Mar 2022
- Dec 2021
- Sep 2021
- Jun 2021
- Mar 2021
- Oper Rev Qtr Cr
- 13
- 15
- 13
- 10
- 20
- 8
- Operating Expenses Qtr Cr
- 12
- 15
- 12
- 8
- 18
- 8
- Operating Profit Qtr Cr
- 1
- 1
- 1
- 2
- 2
- 1
- Depreciation Qtr Cr
- 0
- 0
- 0
- 1
- 1
- 0
- Interest Qtr Cr
- 0
- 0
- 0
- 0
- 1
- 0
- Tax Qtr Cr
- 0
- 0
- 0
- 0
- 0
- 0
- Net Profit Qtr Cr
- 0
- 0
- 0
- 0
- 1
- 0
Concord Drugs Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 13
- Bearish Moving Average
- ___
- 3
- 20 Day
- 26.29
- 50 Day
- 26.29
- 100 Day
- 27.19
- 200 Day
- 29.24
- 20 Day
- 25.69
- 50 Day
- 25.76
- 100 Day
- 27.34
- 200 Day
- 29.25
Concord Drugs Resistance and Support
- First Resistance
- 28.05
- Second Resistance
- 28.55
- Third Resistance
- 29.15
- First Resistance
- 26.95
- Second Resistance
- 26.35
- Third Resistance
- 25.85
- RSI
- 58.37
- MFI
- 46.53
- MACD Single Line
- 0.23
- MACD
- 0.49
Concord Drugs Delivery and Volume
- Period
- NSE + BSE
Volume Avg - NSE + BSE
Delivery Volume Avg - NSE + BSE
Delivery Volume %
- Day
- 4,984
- 400,116
- 80.28
- Week
- 5,412
- 422,476
- 78.07
- 1 Month
- 4,706
- 411,711
- 87.48
- 6 Month
- 4,532
- 371,100
- 81.88
Concord Drugs Result Highlights
Concord Drugs Synopsis
BSE-Medical-Diversified
Concord Drugs belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 51.36 Cr. and Equity Capital is Rs. 8.74 Cr. for the Year ended 31/03/2021. Concord Drugs Ltd. is a Public Limited Listed company incorporated on 24/04/1995 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24230TG1995PLC020093 and registration number is 020093.- Market Cap
- 24
- Sales
- 51
- Shares in Float
- 0.45
- No of funds
- Yield
- Book Value
- 0.85
- U/D Vol ratio
- 1.1
- LTDebt / Equity
- 9
- Alpha
- 0.03
- Beta
- 0.59
Concord Drugs
- Owner Name
- Jun-22
- Mar-22
- Dec-21
- Sep-21
- Promoters
- 49%
- 49%
- 49%
- Individual Investors
- 50.67%
- 50.65%
- 50.47%
- Others
- 0.33%
- 0.35%
- 0.53%
Concord Drugs Management
- Name
- Designation
- Mr. S Nagi Reddy
- Chairman & Wholetime Director
- Mr. T Narsimha Reddy
- Managing Director
- Mr. S Koni Reddy
- Executive Director & CFO
- Ms. P Chandra Kala
- Independent Director
Concord Drugs Forecast
Price Estimates
Concord Drugs Corporate Action
- Date
- Purpose
- Remarks
- 2022-08-06
- Quarterly Results
- 2022-05-30
- Audited Results
- 2022-02-14
- Quarterly Results
- 2021-10-18
- Quarterly Results
- 2021-08-13
- Quarterly Results
Concord Drugs FAQs
What is Share Price of Concord Drugs ?
Concord Drugs share price is ₹27 As on 19 August, 2022 | 06:33
What is the Market Cap of Concord Drugs ?
The Market Cap of Concord Drugs is ₹24 Cr As on 19 August, 2022 | 06:33
What is the P/E ratio of Concord Drugs ?
The P/E ratio of Concord Drugs is 22 As on 19 August, 2022 | 06:33
What is the PB ratio of Concord Drugs ?
The PB ratio of Concord Drugs is 0.8 As on 19 August, 2022 | 06:33